1. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.
- Author
-
Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, and Kumar R
- Subjects
- 25-Hydroxyvitamin D3 1-alpha-Hydroxylase genetics, Animals, Calcitriol blood, Cytochrome P-450 Enzyme System genetics, Fibroblast Growth Factor-23, Fibroblast Growth Factors physiology, Humans, Opossums, Proto-Oncogene Proteins antagonists & inhibitors, Rats, Sodium metabolism, Sodium-Phosphate Cotransporter Proteins, Steroid Hydroxylases genetics, Symporters physiology, Vitamin D metabolism, Vitamin D3 24-Hydroxylase, Wnt Proteins, Kidney metabolism, Osteomalacia metabolism, Paraneoplastic Syndromes metabolism, Phosphates metabolism, Proto-Oncogene Proteins physiology, Zebrafish Proteins
- Abstract
Tumors associated with osteomalacia elaborate the novel factor(s), phosphatonin(s), which causes phosphaturia and hypophosphatemia by cAMP-independent pathways. We show that secreted frizzled-related protein-4 (sFRP-4), a protein highly expressed in such tumors, is a circulating phosphaturic factor that antagonizes renal Wnt-signaling. In cultured opossum renal epithelial cells, sFRP-4 specifically inhibited sodium-dependent phosphate transport. Infusions of sFRP-4 in normal rats over 2 hours specifically increased renal fractional excretion of inorganic phosphate (FEPi) from 14% +/- 2% to 34% +/- 5% (mean +/- SEM, P < 0.01). Urinary cAMP and calcium excretion were unchanged. In thyro-parathyroidectomized rats, sFRP-4 increased FEPi from 0.7% +/- 0.2% to 3.8% +/- 1.2% (P < 0.05), demonstrating that sFRP-4 inhibits renal inorganic phosphate reabsorption by PTH-independent mechanisms. Administration of sFRP-4 to intact rats over 8 hours increased FEPi, decreased serum phosphate (1.95 +/- 0.1 to 1.53 +/- 0.09 mmol/l, P < 0.05) but did not alter serum 1alpha, 25-dihydroxyvitamin D, renal 25-hydroxyvitamin D 1alpha-hydroxylase cytochrome P450, and sodium-phosphate cotransporter mRNA concentrations. Infusion of sFRP-4 antagonizes Wnt action as demonstrated by reduced renal beta-catenin and increased phosphorylated beta-catenin concentrations. The sFRP-4 is detectable in normal human serum and in the serum of a patient with tumor-induced osteomalacia. Thus, sFRP-4 displays phosphatonin-like properties, because it is a circulating protein that promotes phosphaturia and hypophosphatemia and blunts compensatory increases in 1alpha, 25-dihydroxyvitamin D.
- Published
- 2003
- Full Text
- View/download PDF